Calls Now Open
2027 Scholar-Innovator and ADDF-Harrington
April 21, 2026
Harrington Discovery Institute at University Hospitals is now accepting full applications for the 2027 Harrington Scholar-Innovator Award for physician-scientists. The award offers successful applicants multiple opportunities for funding in addition to expertise from pharma-experienced leaders with a track record of bringing...
Continue Reading
April 16, 2025
Unique program for physician-scientists to advance promising discoveries into medicines Continue Reading
March 19, 2025
2025 Harrington Prize for Innovation in Medicine recognizes groundbreaking contributions in the creation of targeted cancer therapies Continue Reading
February 18, 2025
Renowned US Neuroscientist and Harvard Professor brings extensive expertise in academia and industry to advance rare disease research Continue Reading
February 05, 2025
Award highlights collaboration between for profit and non-profit achieving great impact Continue Reading
January 27, 2025
At 18 weeks pregnant, Lindsey learned her baby had severe spina bifida. She joined UC Davis’s groundbreaking CuRe Trial combining fetal surgery and stem cells. Over a year later, her son is thriving. Continue Reading
January 15, 2025
Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading
December 11, 2024
An off-the-shelf drug shows promise as a low-cost topical treatment for psoriasis. New findings highlight benzamil’s potential to reduce inflammation and skin cell overgrowth without steroids or immune suppression. Continue Reading
December 03, 2024
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival Continue Reading
November 15, 2024
Oxford, UK – 15th November 2024 – (or ‘the Company’, www.alveogene.com), a company focused on transforming rare respiratory disease outcomes using inhaled gene therapy, announces that it has been granted a Rare Pediatric Disease Designation (RPDD) by the US Food & Drug Administration (FDA) for AVG-002, its novel... Continue Reading